Using existing NHS datasets to determine outcomes of cancer medicines: a feasibility study

Kelly Baillie, Tanja Mueller, Jiafeng Pan, Christine Crearie, Jennifer Laskey, Robert Jones, Marion Bennie

Research output: Contribution to conferencePoster

14 Downloads (Pure)

Abstract

Based on recent clinical trial evidence, updated treatment guidelines in the UK recommend high-intensity statin therapy (atorvastatin 80mg) for secondary prevention of cardiovascular disease. However, with this high statin dose, there are concerns about a potential increase in the incidence of statin-related side effects, which might affect patients’ adherence and, in turn, clinical outcomes. Hence, this study aimed to evaluate the effect of statin intensity on adherence and persistence to therapy.
Original languageEnglish
Number of pages2
Publication statusAccepted/In press - 18 Jun 2018
Event34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management - The Prague Congress Centre, Prague, Czech Republic
Duration: 22 Aug 201826 Aug 2018

Conference

Conference34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
CountryCzech Republic
CityPrague
Period22/08/1826/08/18

Keywords

  • cancer medicines
  • medicine results

Cite this